Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2

Not yet recruiting

Conditions: HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: S-1
Drug: Capecitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 110

Registration Number: NCT06730373

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳
Shengli Oilfield Central Hospital, Dongying, Shandong, China

and more 16 locations

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Nimotuzumab
Drug: Sintilimab
Drug: Paclitaxel-albumin
Drug: Cisplatin

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 112

Registration Number: NCT06718205

Locations: 🇨🇳
Feng Wang, Zhengzhou, Henan, China

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Sintilimab
Drug: Chemotherapy
Radiation: radiotherapy

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 52

Registration Number: NCT06709417

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/Microsatellite Instability-high, Locally Advanced Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Biological: Sintilimab

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Yugui Lian

Target Recruit Count: 96

Registration Number: NCT06698757

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Irinotecan liposome injection Ⅱ
Drug: Sintilimab

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 27

Registration Number: NCT06697366

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Phase 2

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Pemetrexed 500 mg/m2
Drug: carboplatin
Drug: Sintilimab

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT06688656

Locations: 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai, China

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Chidamide

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-20

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 46

Registration Number: NCT06685276

Locations: 🇨🇳
China PLAGH, Beijing, China

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma (NPC)

Interventions: Drug: Sintilimab

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 150

Registration Number: NCT06680115

Locations: 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Phase 2

Not yet recruiting

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: Ultrafractionated RT and CGA Guided systemic treatment.
Other: data prospectively collected
Radiation: Ultrafractionated Radiotherapy
Drug: Sintilimab
Drug: Fluorouracil
Drug: Raltitrexed
Drug: Oxaliplatin
Drug: Irinotecan (CPT-11)

First Posted Date: 2024-10-22

Last Posted Date: 2024-10-28

Lead Sponsor: Fudan University

Target Recruit Count: 124

Registration Number: NCT06652412

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy